Executive Brief

News Report

The News: FDA approves bulevirtide for chronic hepatitis delta virus infection.
Clinical Win: First FDA-approved treatment for HDV, addressing a critical need.
Target Specialty: Gastroenterology

Key Data at a Glance

Combined response rate at week 48: 48%
Undetectable HDV RNA at week 48: 20%

The FDA approved bulevirtide (Hepcludex) for the treatment of chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis on May 22, 2026. This marks the first FDA-approved therapy for HDV, a serious condition that can lead to liver fibrosis, cancer, and failure, addressing a significant unmet medical need for patients.

Clinical Context

Chronic hepatitis delta virus (HDV) infection is a severe form of liver disease that occurs only in individuals who are also infected with hepatitis B virus (HBV). It is estimated that approximately 12 million people worldwide are co-infected with HBV and HDV, making it a critical public health issue. HDV infection can lead to rapid progression of liver disease, including cirrhosis and hepatocellular carcinoma, significantly increasing the risk of liver-related mortality. Current treatment options for HDV have been limited, with no FDA-approved therapies available until now, leaving patients with few options for managing their disease. The approval of bulevirtide, a novel virion entry inhibitor, represents a breakthrough in the management of HDV, providing hope for improved outcomes in this patient population.

Key Findings

The MYR301 trial showed bulevirtide reduced HDV RNA levels with a combined response of 48% at week 48 compared to 2% in the delayed treatment group (HR not applicable) [1].

The trial enrolled 1,000 adults with chronic hepatitis delta virus infection, including those without cirrhosis and those with compensated cirrhosis [1].

Event rates: 20% of patients receiving bulevirtide achieved undetectable HDV RNA at week 48 compared to 0% in the delayed treatment group [1].

The primary endpoint was defined as undetectable HDV RNA or a decline of ≥2 log 10 IU/mL from baseline and normalization of aminotransferase (ALT) levels at week 48 [1].

What This Means for Clinical Practice

Bulevirtide is now available for adults with chronic hepatitis delta virus infection, providing a much-needed treatment option for a condition previously lacking FDA-approved therapies. Clinicians managing patients with HDV can now offer bulevirtide as part of their treatment strategy, particularly for those at risk of rapid disease progression. The ability to achieve undetectable HDV RNA levels is critical for improving long-term liver health and reducing the risk of severe complications associated with HDV infection. Ongoing monitoring and assessment of patient response to bulevirtide will be essential, especially considering the potential for severe acute exacerbations of HDV and HBV upon discontinuation of treatment. The integration of this new therapy into clinical practice will require careful consideration of individual patient circumstances and ongoing education about the management of HDV infection.

Clinical Perspective

Workflow: Clinicians will need to incorporate bulevirtide into treatment plans for patients with chronic HDV infection, ensuring appropriate monitoring.

Economics: The introduction of bulevirtide may impact healthcare costs, but it could reduce long-term complications and hospitalizations related to HDV.

Patient Outcomes: Patients treated with bulevirtide may experience improved liver health and reduced risk of severe liver-related complications.

Dr. Sanjay Iyer, Gastroenterology

References

FDA — FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection

FDA Approves Bulevirtide for Chronic Hepatitis Delta Virus: First Treatment Available

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Gastroenterology in your inbox.

Related Drug Updates

FDA Approves Bulevirtide for Chronic Hepatitis Delta Virus: New Treatment Algorithm Released

FDA Approves Bulevirtide for Chronic Hepatitis Delta Virus: First Treatment Option Available

FDA Approves New Biologics Algorithm for Ulcerative Colitis: Golimumab, Vedolizumab, Upadacitinib, and More

Verified HCP Portal